Synthetic DNA Guides Allow CRISPR to Edit DNA and Target RNA

Summary

CRISPR is famous for acting like molecular scissors that can edit DNA, relying on an RNA molecule to guide it to the right spot. However, producing these RNA guides can be complex, expensive, and unstable. Now, scientists have found a way to swap that traditional RNA guide for a synthetic DNA version. Known as pseudo-guide DNA, or simply ΨDNA, this new tool allows specific CRISPR enzymes called Cas12 to target and interact with RNA instead.

To make this work, researchers had to get creative with the molecule's structure. They engineered the synthetic DNA guide backward, adding a special structural handle that mimics the natural shape of traditional CRISPR guides. This shape holds the CRISPR enzyme perfectly in place. When put to the test, the new system performed brilliantly. It correctly identified the RNA of the Hepatitis C virus in clinical samples with 100 percent accuracy. It also successfully blocked specific, targeted RNA messages inside human cells, reducing their activity by 70 to 95 percent.

Perhaps the most exciting feature of this new system is its ability to multitask. By delivering both a traditional RNA guide and the new synthetic DNA guide at the same time, scientists can instruct a single CRISPR enzyme to edit a cell's permanent DNA code while simultaneously turning down the volume on its temporary RNA messages.

Why it matters.

Because DNA is significantly cheaper to synthesize and has a much longer shelf life than RNA, this innovation could make CRISPR technologies more accessible and affordable. In the short term, this points to highly sensitive, low-cost diagnostic tests for viruses like Hepatitis C. In the long term, having a single tool that can simultaneously alter a cell's permanent genome and control its temporary genetic messages offers profound possibilities for treating complex genetic diseases.

However, it is important to note that this research is still in an early proof-of-concept stage. The experiments were conducted in laboratory test tubes and cultured human cells using specific versions of the Cas12 enzyme. Before these DNA guides can be used in clinical treatments for patients, scientists will need to conduct extensive testing in living organisms to ensure the system is both safe and effective.

From the source

The story in numbers.

Accuracy in hepatitis C virus RNA detection: 100%
Multiplex knockdown of intracellular RNA transcripts: 70–95%
Cas12 orthologs evaluated: 8

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Swapping RNA for DNA gives CRISPR a powerful new target

The gene-editing tool known as CRISPR has revolutionized biology, traditionally relying on a molecule called guide RNA to direct molecular scissors to a specific piece of DNA. However, researchers have discovered a surprising twist. A specific type of molecular scissors known as a Cas12 nuclease can actually be driven by a different genetic navigator. Instead of using traditional guide RNA, this enzyme can utilize guide DNA. This simple substitution fundamentally changes how the tool behaves in a cell. When scientists swap the guide RNA for guide DNA, the Cas12 nuclease stops targeting DNA and instead switches its focus to targeting RNA. RNA is the genetic messenger that helps carry instructions from our genes to the rest of the cell. By just changing the steering mechanism, scientists can completely redirect the cutting machinery to a brand new molecular target. While this discovery significantly expands the overall versatility of the CRISPR toolkit, it is still very preliminary. The current reports are based on an early-stage perspective and lack the quantitative data, clinical validation, and sample size metrics needed to fully understand how well it works in complex organisms.

Nature Biotechnology1 min read

Blood Immune Cells May Drive Spinal Cord Damage in ALS

Amyotrophic lateral sclerosis (ALS) is a severe condition that causes a progressive loss of nerve cells in the brain and spinal cord. While scientists have spent decades studying why these neurons fail, recent research published in Nature Neuroscience points to an unexpected culprit. The study reveals that the immune system is not merely reacting to the disease, but actually acts as an active driver of ALS pathology. To uncover this, researchers used advanced techniques called single-cell and spatial transcriptomic profiling. These tools allow scientists to look at the genetic activity of individual cells and map their exact physical locations in the body. Using these methods, the team observed that immune cells from the bloodstream are infiltrating the central nervous system. Once there, these immune cells undergo a reprogramming process that directly links changes in the blood to the severe spinal cord damage seen in ALS patients.

Nature Neuroscience1 min read

A Domino Effect: How the Immune System Accelerates ALS

Amyotrophic lateral sclerosis, commonly known as ALS, is a devastating disease that gradually destroys the nerve cells responsible for movement. For years, scientists have puzzled over why the condition progresses rapidly in some patients while others survive much longer. Now, researchers at Northwestern University have uncovered a domino-like cascade that helps explain how the disease unfolds. Rather than a single catastrophic event, ALS appears to start with an internal breakdown inside motor neurons involving a toxic buildup of a protein called TDP-43. This initial damage then triggers a secondary, highly destructive response from the body's own immune system. By examining blood and spinal cord samples from hundreds of living and deceased patients, the scientists mapped out exactly where and how this immune reaction occurs. They discovered that inflamed immune cells from the bloodstream travel into the central nervous system, gathering directly at the sites where motor neurons are dying and toxic proteins are accumulating. Patients with the fastest disease progression had the most intense spinal cord inflammation and higher activity in complement genes, which produce proteins that act as the body's first line of immune defense against damage. Interestingly, the study also revealed that this immune response looks different depending on the root cause of the patient's condition. By analyzing the genetic instructions inside individual cells, the researchers found distinct immune patterns when comparing genetic and non-genetic forms of ALS. This suggests that the immune system reacts uniquely to different variations of the disease.

GEN2 min read

Follow your curiosity.

Synthetic DNA Guides Allow CRISPR to Edit DNA and Target RNA

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Swapping RNA for DNA gives CRISPR a powerful new target

Blood Immune Cells May Drive Spinal Cord Damage in ALS

A Domino Effect: How the Immune System Accelerates ALS

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Swapping RNA for DNA gives CRISPR a powerful new target

Blood Immune Cells May Drive Spinal Cord Damage in ALS

A Domino Effect: How the Immune System Accelerates ALS

A little science goes a long way.